Objective This study was aimed to assess the bioequivalence of randomly selected brands of ofloxacin and its levo-isomer, levofloxacin tablets marketed in Nigeria.
Method Bioavailability assessment was conducted by measuring the concentration of drugs in the urine and bioavailability data was presented as cumulative quantity of drugs recovered in urine in 36 hours. Microbiological assay technique was used to analyze urine samples.
Main Outcome Measure Cumulative quantity of drugs recovered in urine in 36 hours and minimum inhibitory concentrations.
Result The five brands of ofloxacin and the three brands of levofloxacin showed the same minimum inhibitory concentration value against the test strain of Staphylococcus aureus of 0.483ìg/ml and 1.953ìg/ml respectively. The result of the percentage cumulative quantity of drug recovered from urine showed that there was no statistical significant difference among ofloxacin and levofloxacin brands.
Conclusion The various brands of ofloxacin (X1 ? X5) and levofloxacin (Y1 ? Y3) in Nigeria exhibited same bioavailability data in vivo and can be said to be bioequivalents.